The lower levels of sLRP-1 in COVID-19 patients compared to healthy controls can, therefore, increase our understanding of LRP1. Variants of the virus, availability of vaccines, health system organization, and local and global changes in the disease phenotype all affect the COVID-19 outcome. This evidence concerns the gene LRP1 and COVID-19.